Tissue & cell · 2025
Activation ADORA1 protects against sepsis-associated acute kidney injury by inhibiting pyroptosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Wei, Pan Kaixin, Xiao Chenggen
Аннотация
BACKGROUND: The ADORA1 is known to provide renoprotection against acute kidney injury. However, the underlying mechanisms remain unclear. The purpose of this study was to investigate whether and how ADORA1 plays a role in renoprotection in sepsis associated acute kidney injury (SA-AKI).
METHODS: Sepsis model was induced by lipopolysaccharide (LPS) in male C57BL/6 mice, 0.9 % NS served as controls. Animals received ADORA1 agonists and antagonist before the LPS. Renal function, histology and pyroptosis markers were assessed, with simultaneous validation by vitro assays.
RESULTS: The animals treated with ADORA1 agonists exhibited higher survival rates and an improved renal functional recovery, attenuated histological lesions and downgraded pyroptosis. Moreover, which down-regulated the expression of cleaved caspase 11 and GSDMD, while the ADORA1 antagonist group exhibit an oppose results.
CONCLUSIONS: ADORA1 protects against SA-AKI, at least in part, through its inhibitory effects on pyroptosis via the noncanonical inflammasome pathway. If our finding may extrapolated to clinical setting, ADORA1 agonist may serve as a clinical strategy to SA-AKI.
METHODS: Sepsis model was induced by lipopolysaccharide (LPS) in male C57BL/6 mice, 0.9 % NS served as controls. Animals received ADORA1 agonists and antagonist before the LPS. Renal function, histology and pyroptosis markers were assessed, with simultaneous validation by vitro assays.
RESULTS: The animals treated with ADORA1 agonists exhibited higher survival rates and an improved renal functional recovery, attenuated histological lesions and downgraded pyroptosis. Moreover, which down-regulated the expression of cleaved caspase 11 and GSDMD, while the ADORA1 antagonist group exhibit an oppose results.
CONCLUSIONS: ADORA1 protects against SA-AKI, at least in part, through its inhibitory effects on pyroptosis via the noncanonical inflammasome pathway. If our finding may extrapolated to clinical setting, ADORA1 agonist may serve as a clinical strategy to SA-AKI.